New

From Note to Ticker, our white paper on autocallable ETFs. Read now →

Help us improve your experience. Please confirm your investor type:

New Whitepaper

From Note to Ticker: Are Autocallable ETFs Changing the Rules of Structured Income?

From Note to Ticker
›ETF Issuers›BMO›ZGHC
ZGHC

BMO Global Health Care Fund Active ETF Series

Active ETFEquity
Not rated

The ZGHC Exchange Traded Fund (ETF) is provided by BMO. This fund is actively managed; it does not track an index. This share class generates a stream of income by distributing dividends.

Advertisement

Advertisement

$21.21
N/A
Data as of 11/19/26
1D price range
N/A
52W price range
N/A
YTD Perf.
+13.39%
YTD Flows
Annualized volatility
Fund AuM
€11M
Share class AuM
€11M
TTM Yield
Tracking Error
Tracking Difference
ISIN
CA09662C1032
TER
0.82%
Inception date
6/26/2023
Issuer
Dividend policy
API
PerformanceDec 31, 2025 - Nov 19, 2026
-10%-5%0%5%10%15%20%JANMARMAYJULSEPNOV
Flows
Join for free to unlock
Data as of 09/30/26
Healthcare
98.33%
Consumer Non-Cyclicals
1.66%
Latest ZGHC news

No content available for this fund

FAQ about ZGHC

ZGHC is an actively managed ETF that invests in the World Health Care segment.
ZGHC carries a total expense ratio (TER) of 0.82%.
ZGHC was introduced to the market on June 26, 2023.
BMO Global Health Care Fund Active ETF Series, ZGHC, is provided by BMO. Learn more about BMO here.
ZGHC oversees €11M in assets as of November 19, 2026.
ZGHC follows a distributing dividend policy, meaning it pays out income to investors.
As of September 30, 2026, ZGHC has significant geographic allocations in USA, Switzerland and United Kingdom.
As of September 30, 2026, ZGHC focuses largely on Healthcare and Consumer Non-Cyclicals.
As of September 30, 2026, ZGHC holds 118 positions in its portfolio, with 74.97% of assets concentrated in its top 15 holdings.
As of September 30, 2026, ZGHC top three holdings include Eli Lilly & Co., Merck & Co., Inc. and Johnson & Johnson.
The base currency of ZGHC is CAD.
Data as of 09/30/26
Eli Lilly & Co.
10.21%
Merck & Co., Inc.
7.60%
Johnson & Johnson
7.14%
UnitedHealth Group, Inc.
6.67%
AstraZeneca PLC
6.58%
AbbVie, Inc.
5.64%
argenx SE
4.86%
Gilead Sciences, Inc.
4.50%
Abbott Laboratories
3.96%
Thermo Fisher Scientific, Inc.
3.59%

Trackinsight
Essentials

A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.

Essential free account includes:
  • More fund data
  • Compare up to 3 funds
  • More screener filters
  • Edit screener columns from 100+ metrics
  • Watchlists for saving your research
  • Portfolio construction and analysis
  • Personal dashboard for live monitoring
Trackinsight Global ETF Survey 2026: ETFs' Next Act: From Access to Selection. Access the report

Advertisement

Trackinsight

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight
© 2014-2026 Trackinsight SA. All rights reserved.
Privacy policy  |  Cookie policy  |    |  Terms of use  |  Imprint
Trackinsight